Coya Therapeutics (COYA) Share-based Compensation (2022 - 2026)
Coya Therapeutics (COYA) posted Share-based Compensation of $7.3 million for Q1 2026, up 561.45% sequentially from $1.1 million in Q4 2025, and up 575.87% YoY from $1.1 million in Q1 2025.
Coya Therapeutics (COYA) Share-based Compensation (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $7.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 575.87% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 120.68% YoY) and the FY2025 annual result came in at $5.1 million, down 5.56% from the prior year.
- Share-based Compensation improved to $7.3 million in Q1 2026 per COYA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.3 million in Q1 2026 and troughed at $21425.0 in Q1 2022.
- A 5-year average of $1.6 million and a median of $435663.0 in 2024 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 971.99% in 2025, down 39.6% in 2025.
- Over 5 years, Share-based Compensation stood at $71429.0 in 2022, then soared by 233.2% to $237999.0 in 2023, then jumped by 232.16% to $790549.0 in 2024, then jumped by 39.6% to $1.1 million in 2025, then soared by 561.45% to $7.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $7.3 million, $1.1 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | 5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.40 Mn |
| Jun 30, 2026 | 5.40 Mn |
| Mar 31, 2026 | 7.30 Mn |
| Mar 31, 2026 | 7.30 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 6.40 Mn |
| Sep 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 7.10 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 790,549.00 |
| Dec 31, 2024 | 790,549.00 |
| Sep 30, 2024 | 775,006.00 |
| Sep 30, 2024 | 775,006.00 |
| Jun 30, 2024 | 662,321.00 |
| Jun 30, 2024 | 662,321.00 |
| Mar 31, 2024 | 435,663.00 |
| Mar 31, 2024 | 435,663.00 |